New hope for toddlers: drug may delay type 1 diabetes

NCT ID NCT05757713

First seen Jan 31, 2026 · Last updated May 05, 2026 · Updated 7 times

Summary

This study tests the safety of a 14-day treatment with teplizumab in 20 children under 8 years old who have early-stage (Stage 2) type 1 diabetes. The goal is to see if the drug is safe and how the body processes it. Teplizumab aims to slow down the disease and delay the need for insulin.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Barbara Davis Center for Diabetes Site Number : 102

    Aurora, Colorado, 80045, United States

  • Centricity Research Site Number : 104

    Columbus, Georgia, 31904, United States

  • Children's Hospital of Philadelphia Site Number : 108

    Philadelphia, Pennsylvania, 19104, United States

  • Indianapolis University Health Riley Hospital for Children Site Number : 110

    Indianapolis, Indiana, 46202, United States

  • MulitCare Institute for Research & Innovation Site Number : 103

    Tacoma, Washington, 98405, United States

  • Sanford Diabetes and Thyroid Clinic Site Number : 106

    Sioux Falls, South Dakota, 57105, United States

  • UBMD Pediactrics Site Number : 105

    Buffalo, New York, 14203, United States

  • UCSF Medical Center Site Number : 107

    San Francisco, California, 94143, United States

  • Vanderbilt Univerity Medical Center Site Number : 109

    Nashville, Tennessee, 37232, United States

  • Yale University School of Medicine Site Number : 101

    New Haven, Connecticut, 06511, United States

Conditions

Explore the condition pages connected to this study.